2023年科研论文发表情况
发布时间：2025-08-20
| 序号 | 发表论文年度月份 | 论文题目 | 中科院分区 | JCR分区 | 期刊（SCI影响因子，2022年） |
| 1 | 2023/3 | Wang P, Jia X, Lu B, Huang H, Liu J, Liu X, Wu Q, Hu Y, Li P, Wei H, Liu T, Zhao D, Zhang L, Tian X, Jiang Y, Qiao Y, Nie W, Ma X, Bai R, Peng C, Dong Z, Liu K. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. Signal Transduct Target Ther. 2023 Mar 6;8(1):96. doi: 10.1038/s41392-023-01329-3. PMID: 36872366; PMCID: PMC9986241. | 1区 | 1区 | 39.1 |
| 2 | 2023/10 | Ye J, Hu Y, Wang C, Lian H, Dong Z. Cellular mechanism of diabetes remission by bariatric surgery. Trends Endocrinol Metab. 2023 Oct;34(10):590-600. doi: 10.1016/j.tem.2023.07.001. Epub 2023 Aug 11. PMID: 37574405. | 1区 | 1区 | 10.9 |
| 3 | 2023/7 | Liu F, Wu Q, Dong Z, Liu K. Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacol Ther. 2023 Jul;247:108458. doi: 10.1016/j.pharmthera.2023.108458. Epub 2023 May 27. PMID: 37245545. | 1区 | 1区 | 13.5 |
| 4 | 2023/4 | Song M, Pang L, Zhang M, Qu Y, Laster KV, Dong Z. Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases. Signal Transduct Target Ther. 2023 Apr 7;8(1):148. doi: 10.1038/s41392-023-01409-4. PMID: 37029108; PMCID: PMC10082069. | 1区 | 1区 | 39.1 |
| 5 | 2023/6 | Zhao S, Li J, Xia Q, Liu K, Dong Z. New perspectives for targeting therapy in ALK-positive human cancers. Oncogene. 2023 Jun;42(24):1959-1969. doi: 10.1038/s41388-023-02712-8. Epub 2023 May 6. PMID: 37149665. | 1区 | 1区 | 8.0 |
| 6 | 2023/5 | Zhou L, Yao N, Yang L, Liu K, Qiao Y, Huang C, Du R, Yeung YT, Liu W, Cheng D, Dong Z, Li X. DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β. Cell Rep. 2023 May 30;42(5):112445. doi: 10.1016/j.celrep.2023.112445. Epub 2023 May 2. PMID: 37141098. | 1区 | 1区 | 8.8 |
| 7 | 2023/5 | Gu T, Tian X, Wang Y, Yang W, Li W, Song M, Zhao R, Wang M, Gao Q, Li T, Zhang C, Kundu JK, Liu K, Dong Z, Lee MH. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint. Front Immunol. 2023 May 2;14:1145028. doi: 10.3389/fimmu.2023.1145028. PMID: 37205112; PMCID: PMC10185823. | 1区 | 1区 | 7.3 |
| 8 | 2023/5 | Wang J, Li J, Cheng D, Zhang K, Liu W, Xue Q, Du R, Zhou L, Yeung YT, Bai R, Huang H, Cui J, Xiang P, Zhi Y, Liu K, Li X, Dong Z. miR-132-3p promotes heat stimulation-induced esophageal squamous cell carcinoma tumorigenesis by targeting KCNK2. Mol Carcinog. 2023 May;62(5):583-597. doi: 10.1002/mc.23504. Epub 2023 Apr 4. PMID: 37014157. | 2区 | 2区 | 4.6 |
| 9 | 2023/8 | Liu X, Zhao S, Wang K, Zhou L, Jiang M, Gao Y, Yang R, Yan S, Zhang W, Lu B, Liu F, Zhao R, Liu W, Zhang Z, Liu K, Li X, Dong Z. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. Nat Commun. 2023 Aug 8;14(1):4779. doi: 10.1038/s41467-023-40343-5. PMID: 37553345; PMCID: PMC10409784. | 1区 | 1区 | 16.6 |
| 10 | 2023/4 | Zhou Y, He X, Jiang Y, Wang Z, Yu Y, Wu W, Zhang C, Li J, Guo Y, Chen X, Liu Z, Zhao J, Liu K, Dong Z. Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma. Front Med. 2023 Apr;17(2):290-303. doi: 10.1007/s11684-022-0956-8. Epub 2022 Dec 29. PMID: 36580233. | 1区 | 1区 | 8.1 |
| 11 | 2023/2 | Liu X, Jiang Y, Zhou H, Zhao X, Li M, Bao Z, Wang Z, Zhang C, Xie Z, Zhao J, Dong Z, Liu K, Guo Z. Dasabuvir suppresses esophageal squamous cell carcinoma growth in vitro and in vivo through targeting ROCK1. Cell Death Dis. 2023 Feb 13;14(2):118. doi: 10.1038/s41419-023-05633-2. PMID: 36781836; PMCID: PMC9924867. | 1区 | 1区 | 9.0 |
| 12 | 2023/4 | He X, Zhou Y, Chen W, Zhao X, Duan L, Zhou H, Li M, Yu Y, Zhao J, Guo Y, Gu H, Jiang Y, Dong Z, Liu K. Repurposed pizotifen malate targeting NRF2 exhibits anti-tumor activity through inducing ferroptosis in esophageal squamous cell carcinoma. Oncogene. 2023 Apr;42(15):1209-1223. doi: 10.1038/s41388-023-02636-3. Epub 2023 Feb 25. PMID: 36841865. | 1区 | 1区 | 8.0 |
| 13 | 2023/7 | Yin S, Zhao S, Li J, Liu K, Ma X, Zhang Z, Wang R, Tian J, Liu F, Song Y, Song M, Zhao R, Yang R, Lee MH, Dong Z. NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway. Cell Mol Life Sci. 2023 Jul 18;80(8):211. doi: 10.1007/s00018-023-04854-0. PMID: 37462735. | 1区 | 1区 | 8.0 |
| 14 | 2023/4 | Wang D, Zhang W, Zhang X, Li M, Wu Q, Li X, Zhao L, Yuan Q, Yu Y, Lu J, Zhao J, Dong Z, Liu K, Jiang Y. Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase. Mol Carcinog. 2023 Apr;62(4):517-531. doi: 10.1002/mc.23503. Epub 2023 Jan 16. PMID: 36645220. | 2区 | 2区 | 4.6 |
| 15 | 2023/8 | Xie X, Laster KV, Li J, Nie W, Yi YW, Liu K, Seong YS, Dong Z, Kim DJ. OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer. Cell Mol Life Sci. 2023 Aug 30;80(9):272. doi: 10.1007/s00018-023-04931-4. PMID: 37646890. | 1区 | 1区 | 8.0 |
| 16 | 2023/4 | Jia X, Wang P, Huang C, Zhao D, Wu Q, Lu B, Nie W, Huang L, Tian X, Li P, Laster KV, Jiang Y, Li X, Li H, Dong Z, Liu K. Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth. J Exp Clin Cancer Res. 2023 Apr 24;42(1):97. doi: 10.1186/s13046-023-02666-5. PMID: 37088855; PMCID: PMC10124032. | 1区 | 1区 | 11.3 |
| 17 | 2023/5 | Li M, Duan L, Wu W, Li W, Zhao L, Li A, Lu X, He X, Dong Z, Liu K, Jiang Y. Vortioxetine hydrobromide inhibits the growth of gastric cancer cells in vivo and in vitro by targeting JAK2 and SRC. Oncogenesis. 2023 May 5;12(1):24. doi: 10.1038/s41389-023-00472-4. PMID: 37147297; PMCID: PMC10163056. | 2区 | 1区 | 6.2 |
| 18 | 2023/12 | Wang P, Laster K, Jia X, Dong Z, Liu K. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Mol Cancer. 2023 Dec 18;22(1):208. | 1区 | 1区 | 37.3 |
| 19 | 2023/6 | Wu W, Xu J, Gao D, Xie Z, Chen W, Li W, Yuan Q, Duan L, Zhang Y, Yang X, Chen Y, Dong Z, Liu K, Jiang Y. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway. Cell Death Dis. 2023 Jun 16;14(6):364. | 1区 | 1区 | 9.0 |
| 20 | 2023/8 | Kang JH, Dong Z, Shin SH. Benefits of Soybean in the Era of Precision Medicine: A Review of Clinical Evidence. J Microbiol Biotechnol. 2023 Aug 28;33(12):1-11. doi: 10.4014/jmb.2308.08016. Epub ahead of print. PMID: 37674385. | 3区 | 3区 | 2.8 |
| 21 | 2023/10 | Paul S, McCourt PM, Le LTM, Ryu J, Czaja W, Bode AM, Contreras-Galindo R, Dong Z. Fyn-mediated phosphorylation of Menin disrupts telomere maintenance in stem cells. bioRxiv [Preprint]. 2023 Oct 4:2023.10.04.560876. doi: 10.1101/2023.10.04.560876. PMID: 37873235; PMCID: PMC10592958. | 预印本 | ||
| 22 | 2023/3 | Roh E, Kim JE, Zhang T, Shin SH, Kim BG, Li J, Ma X, Lee KW, Dong Z. Orobol, 3'-hydroxy-genistein, suppresses the development and regrowth of cutaneous SCC. Biochem Pharmacol. 2023 Mar;209:115415. doi: 10.1016/j.bcp.2023.115415. Epub 2023 Jan 16. PMID: 36657604. | 2区 | 1区 | 5.8 |
| 23 | 2023/6 | Yang Y, Zheng X, Ni P, Li D, Dan Q, Wang X, Wang Y, Sun Y, Liu K, Dong Z, Ge H. Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. Int J Oncol. 2023 Jan;62(1):12. doi: 10.3892/ijo.2022.5460. Epub 2022 Dec 1. PMID: 36453241; PMCID: PMC9747191. | 2区 | 2区 | 5.2 |
| 24 | 2023/2 | Kwak AW, Lee JY, Lee SO, Seo JH, Park JW, Choi YH, Cho SS, Yoon G, Lee MH, Shim JH. Echinatin induces reactive oxygen species-mediated apoptosis via JNK/p38 MAPK signaling pathway in colorectal cancer cells. Phytother Res. 2023 Feb;37(2):563-577. doi: 10.1002/ptr.7634. Epub 2022 Oct 2. PMID: 36184899. | 1区 | 1区 | 6.1 |
| 25 | 2023/4 | Yang H, Ai H, Zhang J, Ma J, Liu K, Li Z. UPS: Opportunities and challenges for gastric cancer treatment. Front Oncol. 2023 Apr 3;13:1140452. doi: 10.3389/fonc.2023.1140452. PMID: 37077823; PMCID: PMC10106573. | 3区 | 3区 | 3.5 |
| 26 | 2023/4 | Ai H, Yang H, Li L, Ma J, Liu K, Li Z. Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers. Front Immunol. 2023 Jun 16;14:1190883. doi: 10.3389/fimmu.2023.1190883. PMID: 37398650; PMCID: PMC10311965. | 2区 | 2区 | 5.7 |
| 27 | 2023/5 | Yuan Q, Chu Y, Li X, Shi Y, Chen Y, Zhao J, Lu J, Liu K, Guo Y. CAFrgDB: a database for cancer-associated fibroblasts related genes and their functions in cancer. Cancer Gene Ther. 2023 Jun;30(6):917-925. doi: 10.1038/s41417-023-00603-4. Epub 2023 Mar 15. PMID: 36922546; PMCID: PMC10281871. | 2区 | 2区 | 4.8 |
| 28 | 2023/10 | Zhang C, Wu Q, Yao K, Jin G, Zhao S, Zhang J, Zheng W, Xu B, Zu Y, Yuan J, Liu K, Guo Y. Sulforaphene suppresses oesophageal cancer growth through mitogen- and stress-activated kinase 2 in a PDX mouse model. Am J Cancer Res. 2023 Oct 15;13(10):4708-4720. PMID: 37970356; PMCID: PMC10636680. | 2区 | 2区 | 3.6 |
| 29 | 2023/12 | Tang J, Qi C, Bai X, Ji M, Wang Z, Luo Y, Ni S, Zhang T, Liu K, Yuan B. Cell Membrane-Anchored DNA Nanoinhibitor for Inhibition of Receptor Tyrosine Kinase Signaling Pathways via Steric Hindrance and Lysosome-Induced Protein Degradation. ACS Pharmacol Transl Sci. 2023 Dec 12;7(1):110-119. doi: 10.1021/acsptsci.3c00190. PMID: 38230289; PMCID: PMC10789140. | 2区 | 2区 | 4.9 |
| 30 | 2023/12 | Luo H, Sun Y, Wang L, Liu H, Zhao R, Song M, Ge H. Targeting endoplasmic reticulum associated degradation pathway combined with radiotherapy enhances the immunogenicity of esophageal cancer cells. Cancer Biol Ther. 2023 Dec 31;24(1):2166763. doi: 10.1080/15384047.2023.2166763. PMID: 36907982; PMCID: PMC10026871. | 2区 | 2区 | 4.4 |
| 31 | 2023/11 | Lee SO, Lee MH, Kwak AW, Lee JY, Yoon G, Joo SH, Choi YH, Park JW, Shim JH. Licochalcone H Targets EGFR and AKT to Suppress the Growth of Oxaliplatin -Sensitive and -Resistant Colorectal Cancer Cells. Biomol Ther (Seoul). 2023 Nov 1;31(6):661-673. doi: 10.4062/biomolther.2023.155. PMID: 37899744; PMCID: PMC10616518. | 3区 | 3区 | 3.0 |
上一篇： 2024年科研论文发表情况
下一篇： 2022年科研论文发表情况
